PERTH, Australia – Medicines Australia condemned a recent report that urged the Australian government to use international reference pricing for drugs reimbursed on the country's Pharmaceutical Benefits Scheme (PBS). Read More
The results of a new Taiwanese study into the little known role of circular RNA (circRNA) in colorectal cancer (CRC) pathogenesis suggest a new approach is needed to treatment of the cancer, in which therapy should not only target proteins, but also non-protein coding RNAs. Read More
TAIPEI, Taiwan – During the two days of talks, roundtables and panel discussions at the recent Biologics World Taiwan 2017, much of the attention speakers devoted to Taiwan focused on what the country is not getting right, from government support and policies, to competing with regional rivals. Read More
TAIPEI, Taiwan – The government here, despite its good intentions, needs to make changes in its approach to the biopharma industry quickly, said speakers during the Biologics World Taiwan 2017 conference. Read More
PERTH, Australia – More patients with Pompe disease in New Zealand will now have access to Sanofi Genzyme's enzyme replacement therapy Myozyme (alglucosidase alfa), but not because the country's single payer will pay for the drug. Rather, Sanofi Genzyme, of Cambridge, Mass., part of Sanofi SA, has stepped in to provide the therapy for free to patients in New Zealand. Read More
TOKYO – Despite being home to world-class biomedical research and large innovative drug and device companies, a lack of an entrepreneurial ecosystem has emerged as a significant challenge for the biotech and med-tech industries. That is a challenge that regulators are now trying to address and overcome. Read More
TAIPEI, Taiwan – The global biotech market is in a period of low productivity, high costs and less-than-ideal levels of efficiency. Such conditions are pushing pharmaceutical firms in the Asia-Pacific region to develop creative strategies that often require looking elsewhere for innovative solutions and products. Read More
